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ABSTRACT
Objective: To assess individualized satisfaction with
migraine treatment, patient expectations, importance rank-
ings, treatment outcomes, and overall satisfaction were
combined using a four-part conceptual model. This article
describes the measurement properties of the Migraine Treat-
ment Satisfaction Measure (MTSM) using participants from
a randomized controlled trial evaluating a Headache Man-
agement Program (HMP).
Methods: Participants completed the ﬁrst two parts of the
MTSM upon enrollment and the ﬁnal two parts at 6 months.
Internal consistency reliability was computed within each
of the four modules. Discriminant validity was ascertained
using Migraine Disability Assessment Survey (MIDAS),
Patient Health Questionnaire-9, and MSFB scores. Conver-
gent validity was established by hypothesized positive corre-
lations between MTSM scores, Medical Outcomes Study
Short-Form (SF-36), MIDAS, and Migraine Symptom Fre-
quency Bother (MSFB).
Results: In total, 124 participants (mean age 45.4 years,
75% women, 59.7% Caucasian) enrolled. Internal consis-
tency for expectations, importance rankings, outcomes, and
satisfaction measures was 0.83, 0.95, 0.86, and 0.95, respec-
tively. As the severity of depression increased, MTSM scores
decreased signiﬁcantly. ANOVA between MTSM scores and
symptom bothersomeness and symptom frequency tertiles
showed a signiﬁcant decrease in satisfaction in the moderate-
to-severe groups. MTSM scores showed expected associa-
tions with MSFB scores (-0.301; P < 0.01), MIDAS (-0.267;
P < 0.01), general health (0.253; P < 0.05), mental health
(0.217; P < 0.05), and vitality subscales of SF-36 (0.214;
P < 0.05). Patients in the HMP reported signiﬁcantly higher
MTSM scores (43.2 vs. 31.4; P < 0.001). Patients on triptans
reported a signiﬁcantly higher satisfaction compared to
patients on analgesics (39.5 vs. 32.9; P < 0.05).
Conclusion: The MTSM is a valid and reliable patient-
reported outcome that can be used to evaluate differ-
ences in treatment satisfaction associated with migraine
therapies.
Keywords: migraine headaches, satisfaction with treatment.
Introduction
The Migraine Treatment Satisfaction Measure
(MTSM) was developed to address the need for a
standardized and individualized approach to the
assessment of satisfaction with migraine treatment. An
earlier conceptual model [1] proposed the measure-
ment of patient satisfaction as an indicator of health-
care quality. Research supports the relationship
between patient satisfaction and treatment-related
behaviors, such as greater satisfaction with care
leading to better adherence to treatment [2–6].
Patients, families, providers, insurers, and adminis-
trators all have an interest in promoting interventions
and medications that are effective, safe, and conve-
nient. Several tools have been developed and tested for
use in measuring patient satisfaction with drug therapy
[7–9] and multidimensional measures have been devel-
oped to measure aspects of care that are important to
people with migraines [10–14].
Qualitative work shows, however, that persons
with migraine headaches consistently express a
variety of expectations about the attributes of
migraine medications they are prescribed: effective
pain relief (complete or rapid), duration of pain
relief, low rate of migraine recurrence, route of
administration (how easy the drug is to take), the
number of doses needed to achieve pain relief, few
side effects, how fast the medication allows return to
normal activities, and effectiveness of relief of asso-
ciated symptoms [10,11,14,15]. Existing measures
fail to detail the speciﬁc aspects of a treatment that
may be associated with satisfaction or dissatisfaction
and therefore generally have lower reliability and
validity compared with multidimensional measures
[9]. Furthermore, distributions of satisfaction ratings
are commonly positively skewed with a majority of
patients expressing high satisfaction.
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Patient satisfaction is an affective response incorpo-
rating the cognitive evaluation of a treatment’s perfor-
mance. Expectations of performance or outcome are a
key variable in determining satisfaction measurement
in psychology and in business. Business customers
are seen as having different expectations for a service
or product and there is a zone of tolerance or gap
between the adequate and desired aspects of the
product. The service quality gap [16] is the gap
between the expected (“what I want”) and the per-
ceived (“what I get”).
Previous qualitative development [17] resulted in an
approach for measuring individual patient satisfaction
with treatment for migraine headaches in a way that
puts a value on drivers of satisfaction. This approach
identiﬁed patient expectations as modiﬁed by patient
values and experience as key inﬂuences on perceived
satisfaction with treatment. Underlying patient pre-
ferences (driven by multiple concepts such as cost,
previous treatment experience, lifestyle, etc.) were rep-
resented in the model as an important generator of a
patient’s expectations about their treatment.
Nine attributes of treatment were identiﬁed and
included in the measurement model (Patrick et al.
2003) [17]. These attributes, identiﬁed by patients in
qualitative research, were as follows: 1) to have total
relief from my migraine pain; 2) to have my migraine
relieved quickly; 3) during a migraine, to be free from
pain for a long time; 4) other than pain, to have no
additional migraine symptoms that bother me; 5) to
have conﬁdence this treatment will work; 6) to have
migraines cause less disruption in my life; 7) to have
my migraine relieved with just one dose of medication;
8) as the medication wears off, to have freedom from
migraine pain returning; and 9) to have a treatment
that is easy to use. The measurement model for this
four-part assessment contains four distinct measures:
1) expectations about the nine attributes of treatment;
2) importance rankings of the nine attributes; 3)
patient-reported outcome for each attribute after the
experience of a new treatment; and 4) an overall evalu-
ation of satisfaction with treatment [17]. This earlier
project produced the initial multistep approach to
evaluating treatment satisfaction as an outcome and
early evaluation results suggested the need for further
application in a clinical trial to complete its testing.
The Duke Center for Clinical Health Policy
Research conducted a randomized controlled trial of
Headache Management Programs (HMP) at three
clinical sites, with a grant from the Agency for Health
Care Research and Quality (AHRQ). The trials were
aimed at reducing headache-related disability, improv-
ing process of care, and reducing management costs
for patients with chronic headache. The MTSM was
included in the measurement package for this commu-
nity headache management intervention to obtain the
data needed to evaluate its measurement properties.
Objectives
The primary aim of this article is to report the further
psychometric performance of the multicomponent
MTSM using data generated from a subset of partici-
pants in a larger, randomized controlled trial of HMP
at Duke University.
Methods
In conjunction with their participation in the larger,
multisite study, at least 100 patients with migraine
headaches were targeted for recruitment into this addi-
tional validation study. Once the patients met the eli-
gibility criteria established in the larger AHRQ grant
study and were enrolled in the larger trial, they were
asked whether they were willing to complete an addi-
tional survey at baseline and at 6 months.
The option of participating in this additional vali-
dation study was presented to both intervention
and control group patients. For intervention group
patients, this occurred when they attended the initial
group educational session that preceded individual
treatment of the HMP program. For control group
patients, this was concurrent with their baseline mea-
sures for the study. Patients who were willing to par-
ticipate were asked to sign a consent form and were
given the baseline MTSM (by mail) to self-administer,
complete and return. Upon completion of the baseline
measure, they received $25 from the study site for their
participation. At 6 months, patients were mailed the
follow-up MTSM measure. Upon receipt of this com-
pleted form, they received another $25.
Patients were included in the AHRQ study if they
were 21 years of age or older, had chronic headache
thought to be of tension-type, migraine, or mixed eti-
ology, intended to continue general medical care at
their current location for the following 12 months;
had a Migraine Disability Assessment Survey (MIDAS)
score greater than 5, and were referred by their
primary care physician as having frequent and/or
difﬁcult-to-manage headaches. Patients were excluded
from enrollment if they were not currently receiving
treatment from a neurologist, and/or not currently
receiving treatment from a headache clinic.
Measures
The MTSM is a four-part assessment [17]:
(Part 1) The Expectations of Treatment for Migraines
(TE-M). The nine items in the TE-M correspond to
nine main attributes of treatment satisfaction for
migraine, and are worded to express the attribute as
an expectation. Each item has a 5-point response scale
unique to what one would expect in a treatment with
1 being the worst case scenario (i.e., “not relieve my
pain at all”) and 5 being the best situation (i.e.,
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“totally relieve my pain”). This part of the MTSM
addresses “ideal expectations.”
(Part 2) The Importance Ranking for Migraine Treat-
ment (IR-M). The IR-M uses a set of nine main
attributes for participants to rank from most impor-
tant to least important. A line is drawn from the
attribute to a place on a 10-cm rating scale with “As
important as can be” at the top to “Not important at
all” at the bottom. The intersection of their drawn line
and the 10-cm line gets scored on a 0- to 100-point
scale. This part of the MTSM addresses “desired
expectations” expressed as importance ratings.
(Part 3) The Outcomes of Treatment for Migraines
(TO-M). The nine items in the TO-M correspond to
the nine main attributes of treatment satisfaction for
migraine, and are worded to express the patient’s view
of their treatment outcome. Each item has a 5-point
response scale indicating the actual outcome of the
treatment with 1 being the worst-case scenario (i.e.,
“did not relieve my pain at all”) and 5 being the best
situation (i.e., “totally relieved my pain”). This part of
the MTSM elicits a self-report of treatment outcomes.
(Part 4) The Satisfaction with Migraine Treatment
(PST-M). The PST-M contains a set of nine items
worded to express the patient’s degree of treatment
satisfaction that correspond to each of the nine main
attributes. Each item has a 0- to 10-point visual analog
response scale with 0 being “The most dissatisﬁed I
could be” and 10 being “The most satisﬁed I could
be.” This part of the MTSM addresses satisfaction of
the actual treatment experience.
The following measures were also included in the
study. The Medical Outcomes Study Short-Form (SF-
36) [18] is a generic measure of functional status using
eight domain scores (physical functioning, physical
role limitations, emotional role limitations, social
functioning, bodily pain, general mental health, vital-
ity, and general health perceptions). Each domain is
scored from 0 “poor health” to 100 “optimal health”
[18]. A migraine symptom list was included which was
comprised of 15 symptoms known to be associated
with migraine headaches. These symptoms (nausea,
vomiting, auras, tiredness, dizziness, palpitations,
problems concentrating, difﬁculty communicating,
weakness in limbs, tingling in limbs, and increased
sensitivity to light, sound, heat, cold, and smell) were
suggested by previous qualitative interviews with
migraine patients and conﬁrmed by clinician input.
Each symptom has seven response options (along with
an option of not having the symptom) ranging from 1
“Not at all bothered” to 7 “A very great deal both-
ered.” The ﬁnal score is the sum of each symptom’s
bothersomeness response ranging from 0 (not having
any symptoms) to 105 (being a very great deal both-
ered by all 15 symptoms).
The MIDAS. The MIDAS is a seven-item question-
naire used to determine the level of pain and disability
caused by headaches and to help health-care profes-
sionals ﬁnd the best treatment [19]. The Patient Health
Questionnaire-9 (PHQ-9) is a set of nine symptoms
addressing depression and anxiety. Each symptom
(based on a recall of 2 weeks) has four response
options ranging from 0 “Not at all” to 3 “Nearly every
day.” The ﬁnal score is the sum of each symptom’s
bothersomeness response ranging from 0 (not having
any symptoms) to 27 (being a very great deal bothered
by all nine symptoms). If respondents score a 5 or
greater, they may have symptoms consistent with a
depressive condition [20].
Statistical Methods
Patient evaluations were conducted at baseline (using
the ﬁrst two parts of the measure) and at 6 months
(for the ﬁnal two parts of the measure). Once collected
by the Duke Center, the validation study data forms
were copied and sent to Health Research Associates
(Seattle, WA) where they were entered along with
accompanying demographic data, various clinical vari-
ables, and comorbid conditions. All analyses were
performed using SPSS for Windows, Version 10.1
(SPSS, Chicago, IL) [21]. Demographic variables were
descriptively analyzed for both the intervention and
control arms using t-tests for continuous variables and
chi-square tests for categorical variables. Psychometric
testing of the MTSM was conducted using the scoring
procedures developed in the earlier pilot study, and the
instrument review criteria developed by the Scientiﬁc
Advisory Committee of the Medical Outcomes Trust
[22]. Standard population and measurement descrip-
tive tables were generated and missing data were
evaluated.
Convergent validity involved comparing the mea-
sures to other logically related scales or items. If
predictions of association are accurate (demonstrate
signiﬁcant correlations), then convergent validity is
achieved. To assess convergent validity, a Spearman
correlation was used to measure the association
between satisfaction with migraine treatment and
general health status (SF-36). Because of the primary
impact of migraine on life disruption, we hypothesized
that the total derived MTSM score will have a strong
association (>0.30) with the MIDAS disability scale.
Guttman-Cronbach’s alpha was calculated to assess
internal consistency reliability for each of the mea-
sures. Alpha statistics were used to analyze additive
scales to determine whether the items within the scale
are highly associated [23]. A minimum correlation of
0.70 is necessary to claim the instrument is internally
consistent and it is preferred to have alpha values
between 0.80 and 0.90 [24].
Assessing known group’s validity involved testing
various hypotheses about how we intuitively believe
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the MTSM scales should work. For the “known
groups” analyses, we looked at treatment satisfaction
by levels of symptom severity, frequency and bother-
someness. ANOVAs with Student-Newman-Keuls
(SNK) comparisons were performed to assess discrimi-
nant validity. Regression analysis was used to identify
a proportionate contribution of the difference between
outcomes/expectations and the importance rank on the
ﬁnal patient reported level of satisfaction. Sensitivity to
change was assessed by examining satisfaction scores
by intervention group (HMP vs. control) using t-tests
to assess group differences.
Scoring Methods
In the previous pilot study, several approaches to
scoring were considered. Most options had inherent
drawbacks in terms of usability and the numbers
required in the data set to develop standardized
weights. The most practical approach was deﬁned as
one that could build a scoring formula to express the
conceptual model, but could be developed on a small
set of sample data. The adopted scoring method was
driven primarily by the conceptual model and involved
a number of weighting assumptions. A regression
analysis was used to identify the relative contribution
of the differences between expectations and treatment
outcomes and between the importance ranking and the
ﬁnal patient-reported level of satisfaction.
Separate regressions were run for each of the nine
main attributes. For each attribute, the patient-
reported (raw) satisfaction item was entered as the
dependent variable and the independent variables were
outcomes/expectation item differences and the item
responses for importance ranking.
This produced nine pairs of regression coefﬁcients
(one for the difference in outcome/expectation and
one for the importance rank for each attribute). The
ﬁnal value used for weighting the outcomes/
expectation score was derived from averaging the
regression coefﬁcients (all of the difference in
outcome/expectation for each attribute) and then all
the values for the importance rank for each attribute.
Therefore, the overall ﬁnal weighting for the impor-
tance ranking came from the process of identifying
and averaging these two sets of regression coefﬁ-
cients. Adjusted weight values derived from the
regression analysis in this sample were 0.80 and 0.20
for outcomes/expectation difference and importance,
respectively.
An exploratory factor analysis with varimax rota-
tion was performed with the nine attribute scores
to evaluate the validity of a single overall score for
treatment satisfaction. The sensitivity of the scoring
method was assessed by comparing the distributions of
the global and the derived MTSM satisfaction scores
against normal curves.
Scoring Steps
Step 1. A score was calculated using the two self-
report parts of the measure for expectations and out-
comes. Using the Bland and Altman theory that two
measures of the same or highly related theme should be
subtracted from one another, expectation (with a 1–5-
response option) was subtracted from outcome (also
a 1–5-response scale). This number was then trans-
formed to a 0- to 100-point scale with higher scores
representing expectations met and lowers scores indi-
cating expectations not met. The resulting variable
represented the difference between what a patient
thought would happen and what actually happened
(expectation modiﬁed by treatment experience/out-
come). This step operationalizes treatment satisfaction
as dependent upon expectations.
Step 2. The adjusted treatment expectations variable
(from step 1) and the raw values given by patients
for importance ranking were each multiplied by the
regression weights. These two values were then
summed to represent “modiﬁed expectations, adjusted
further for importance.”
Step 3. The value derived in step 2 was then divided by
10 to create a variable on a 0 to 10 scale that could be
used as the ﬁnal value for modifying the raw satisfac-
tion scores.
Step 4. The derived treatment satisfaction values were
generated by multiplying the raw individual satisfac-
tion scores from the fourth part of the measure (Satis-
faction items) with the variable created in step 3 (both
on 0–10-response scales).
Scoring formula:
Attribute Score out exp
Imp
= −( ) +( ) ( )∗( )∗ +(
∗( )) ∗
4 8 100 0 80
0 20 10
.
. Satisfaction
Step 5. The ﬁnal overall MTSM treatment satisfaction
score was generated by summing the nine different
derived attribute scores generated in step 4. TheMTSM
score represents patient expectations about their treat-
ment, modiﬁed by the treatment experience, weighted
by their adjusted importance values, and used as to
modify raw satisfaction values and yield a more sensi-
tive expression of overall treatment satisfaction.
Sensitivity to Change
The measurement model calls for a study design where
the ﬁrst two parts of the measure are administered
before the onset of a new treatment and the remaining
two parts at a later point in time. This allows theMTSM
score to reﬂect a change related to a new treatment.
Sensitivity was evaluated by comparing MTSM scores
for those receiving and not receiving the management
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program. Signiﬁcant differences were also evaluated
across the groups in the management program who
were receiving different types of medications.
Results
Population Description
The mean age of the overall sample (n = 124) at base-
line was 45.4 years (SD  11.6); 75% were female and
59.7% were Caucasian. In the intervention arm
(HMP), the mean age of the participants was 45.3
(SD  11.6) years, 93.3% were women, and 65% of
the participants were Caucasian. In the control arm
(no HMP), the mean age of the participants was 45.4
(SD  11.1) years, 85.9% were women, and 64.1%
were Caucasian. The participants in the intervention
and control arms did not differ statistically in terms of
age, gender, and race, F = 0.041 (0.840), c2 = 0.773
(0.379), and c2 = 1.901 (0.387), respectively.
Scale Results
The correlation between raw satisfaction scores and
the MTSM adjusted satisfaction scores using Spear-
man methods was 0.96. Internal consistency results for
the expectations, outcomes, and satisfaction parts of
the measure were a = 0.83, 0.86, and 0.95, respec-
tively. The relatively high alpha values are consistent
with the earlier development work and were expected
due to the structure and design of the measure, the
scoring, and the use of one variable to create the other.
Results of the exploratory factor analysis indicated a
single factor, with 68.5% of the variance explained.
Known Groups Validity
Migraine Treatment Satisfaction Measure scores were
analyzed by groups of known levels of disability, as
deﬁned by the MIDAS score. The results of this analy-
sis are shown below in Table 1. Though the results are
not statistically signiﬁcant, it is seen that as the level of
disability due to migraine pain increases, the mean
MTSM score decreases.
Migraine Treatment Satisfaction Measure scores
were analyzed by severity of depression, based on the
number of depressive symptoms experienced, as
deﬁned by the PHQ-9 score. The results of this analysis
are shown below in Table 2. The results show that as
the intensity of depressive symptoms experienced
increases, the mean MTSM score decreases signiﬁ-
cantly. SNK comparisons of the ANOVA results
showed that the MTSM scores for patients with
highest depressive symptoms were signiﬁcantly differ-
ent from MTSM scores for patients with threshold and
mild depressive symptoms.
Migraine Treatment Satisfaction Measure scores
were assessed by the severity of bothersome symptoms
experienced, as deﬁned by the Migraine Symptom Fre-
quency Bother (MSFB) score. The results shown in
Table 3 indicated that as the intensity/severity of both-
ersome symptoms experienced increases, the mean
MTSM score decreased signiﬁcantly. SNK comparisons
of the ANOVA results showed that the MTSM scores
for patients with mild symptom-bothersomeness were
signiﬁcantly different from MTSM scores for patients
with moderate and severe bothersomeness.
Migraine Treatment Satisfaction Measure scores
were also analyzed by the frequency of bothersome
symptoms experienced, as deﬁned by the MSFB score.
The results of this analysis are shown below in Table 4.
The results show that as the frequency of bothersome
symptoms experienced increases, the mean MTSM
score decreases signiﬁcantly, that is patients with mild
symptom frequency were signiﬁcantly different from
MTSM scores for patients with moderate and severe
symptom frequency.
Convergent Validity
The MTSM was expected to be more highly correlated
with both the bodily pain and role-emotional subscales
of the SF-36 than the other subscales. The strongest
Table 1 MTSM by MIDAS
Migraine Disability Assessment
Survey (MIDAS) n
Migraine Treatment
Satisfaction Score (MTSM)
Mean (SD)
Little or no disability 34 39.4 (17.0)
Mild disability 26 40.8 (16.5)
Moderate disability 21 36.1 (13.8)
Severe disability 29 31.7 (14.8)
F-stat (Sig.) = 1.901 (0.134)
MTSM, Migraine Treatment Satisfaction Measure.
Table 2 MTSM by PHQ-9
Patient Health Questionnaire-9
(PHQ-9) n
Migraine Treatment
Satisfaction Score (MTSM)
Mean (SD)
Threshold depression 16 43.2 (16.9)
Mild depression 80 37.9 (15.0)
High depression 16 27.1 (15.7)
F-stat (Sig.) = 4.728 (0.011)*
*P < 0.05.
MTSM, Migraine Treatment Satisfaction Measure.
Table 3 MTSM by MSFB (bothersomeness)
MSFB (bothersomeness) n
Migraine Treatment Satisfaction
Score (MTSM)
Mean (SD)
Low symptom bother 57 42.3 (16.4)
Moderate symptom bother 37 32.6 (13.4)
Severe symptom bother 26 31.5 (13.9)
F-stat (Sig.) = 6.888 (0.001)*
*P < 0.05.
MSFB, Migraine Symptom Frequency Bother; MTSM, Migraine Treatment Satisfaction
Measure.
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MTSM correlations were with the vitality (0.214),
mental health (0.217), general health (0.253), and
bodily pain (0.189) subscales. These relationships are
lower than expected, but signiﬁcant. Other correla-
tions with SF-36 subscales were not signiﬁcant.
The strongest association was seen between the
derived MTSM score and the symptom score (0.301;
P < 0.01). Of the individual items, the strongest corre-
lations were seen with Item C (pain-free for long time)
(0.371; P < 0.01), and Item F (less disruption) (0.325;
P < 0.01). Signiﬁcant associations were seen with
Item A (total relief) (0.22; P < 0.05). Item D (derived
symptom satisfaction) (0.218; P < 0.05), Item E (con-
ﬁdence in treatment) (0.087; P < 0.01), Item G (relief
with one dose) (0.094; P < 0.05), Item H (freedom
from pain return) (0.28; P < 0.01).
Another strong association was between the
derived MTSM score and the MIDAS disability
score (0.267; P < 0.01). Of the individual items, sig-
niﬁcant correlations were seen with Item A (total
relief) (0.265; P < 0.01), Item C (pain-free for long
time) (0.198; P < 0.05), and Item F (less disruption)
(0.218; P < 0.05).
The relationship between SF-36 subscales and the
item scores from the Satisfaction part of the measure
are indicated in the following paragraphs. The derived
Migraine Treatment Satisfaction Measure (MTSM)
score showed signiﬁcant correlations with Vitality
(0.214; P < 0.05), Mental health (0.217; P < 0.05),
Bodily pain (0.189; P < 0.05), and General health
(0.253; P < 0.01) subscales of SF-36. Item F (less dis-
ruption) (0.22; P < 0.05) showed signiﬁcant associa-
tion with the Role-emotional subscale of SF-36.
Among the Social-functioning subscale, Item F (less
disruption) (0.22; P < 0.05) and Item I (easy to use)
(0.222; P < 005) showed signiﬁcant correlations. In
the Vitality subscale, Item E (conﬁdence in treat-
ment) (0.201; P < 0.05), Item F (less disruption)
(0.256; P < 0.01), Item G (relief with one dose) (0.225;
P < 0.05), Item H (freedom from pain return) (0.204;
P < 0.01), and Item I (easy to use) (0.215; P < 0.05)
showed signiﬁcant associations.
Item E (conﬁdence in treatment) (0.185; P < 0.05),
Item F (less disruption) (0.286; P < 0.01), Item G (relief
with one dose) (0.184; P < 0.05), and Item H (freedom
from pain return) (0.198; P < 0.05) showed signiﬁcant
associations with the mental health subscale. Item F
(less disruption) (0.193; P < 0.05), Item G (relief with
one dose) (0.188; P < 0.05), and Item H (freedom from
pain return) (0.192; P < 0.05) showed signiﬁcant asso-
ciation with the SF-36 Bodily pain subscale.
Item A (total relief) (0.195; P < 0.05), Item C (pain-
free for long time) (0.191; P < 0.05), Item D (derived
symptom satisfaction) (0.208; P < 0.05), Item E (con-
ﬁdence in treatment) (0.186; P < 0.05), Item F (less
disruption) (0.275; P < 0.01), and Item G (relief with
one dose) (0.239; P < 0.05) showed signiﬁcant associa-
tion with the SF-36 general health subscale.
Sensitivity of the Scoring Algorithm
The sensitivity of the scoring method can be seen in
Figures 1 and 2. Figure 1 shows the frequency of the
global satisfaction item. The distribution is skewed to
the right, with most of the participants reporting
higher levels of satisfaction. Figure 2 shows the fre-
quency of the derived MTSM satisfaction score in the
same population, which approximates a normal dis-
tribution. The scoring algorithm incorporates the
patients’ responses from all the components (expecta-
tions, importance ratings, and treatment outcomes) to
enhance or disenhance the raw satisfaction score.
Table 5 lists the actual ranges of the derived MTSM
score for each global satisfaction item score.
Sensitivity to Change
We hypothesized that patients in the HMP would have
higher satisfaction than those not participating in the
program. The results showed that patients in the HMP
experienced signiﬁcantly higher satisfaction (mean
MTSM 43.2) when compared to those not in the HMP
(mean MTS 31.4) (t-stat = -4.376; P < 0.001). Table 6
shows that for all nine items of the MTSM, patients
in the HMP reported higher satisfaction compared to
those not in the HMP. We also found that patients on
triptans reported a signiﬁcantly higher satisfaction
compared to patients on analgesics (39.5 vs. 32.9;
P < 0.05).
Discussion
This study built on our previously published work to
reﬁne the conceptual and measurement model of a
standardized and individualized MTSM. In this article,
we utilized data generated in a randomized controlled
trial of HMP to assess and reﬁne current scoring
methods and to reevaluate the psychometric perfor-
mance of the multicomponent MTSM.
In this, we reapplied the previous scoring to the
current clinical trial data set to generate revised
weights (0.80 for outcomes/expectations difference
and 0.20 for importance). Once the MTSM was
scored, it was found that all scores decreased with
Table 4 MTSM by MSFB (symptom frequency)
MSFB (symptom frequency) n
Migraine Treatment
Satisfaction Score (MTSM)
Mean (SD)
Mild 30 45.1 (14.3)
Moderate 27 31.6 (16.2)
Severe 63 35.4 (15.7)
F-stat (Signif) = 6.442 (0.002)*
*P < 0.05.
MSFB, Migraine Symptom Frequency Bother; MTSM, Migraine Treatment Satisfaction
Measure.
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increased depressive symptoms, migraine symptom
frequency and bothersomeness.
Convergent associations were low between the
MTSM and the SF-36 subscales. This is most likely
related to the nature of the SF-36 being a global
measure and the MTSM content being speciﬁc to
the migraines. MTSM correlations were higher with
the two migraine-speciﬁc measures (MIDAS and the
migraine symptom) but were still relatively low. This
might be related to the difference in constructs mea-
sured (quality of life, symptoms, and satisfaction).
The test of known groups validity showed that
there was a signiﬁcant difference in MTSM score
between groups of patients according to the number of
depressive symptoms experienced. There was a signiﬁ-
cant difference in MTSM scores between groups of
patients according to the frequency and bothersome-
ness of migraine symptoms experienced. These results
Global Satisfaction
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Figure 1 Frequency of global satisfaction
scores.
Derived MTSM
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Figure 2 Frequency of derived MTSM sco-
res. MTSM, Migraine Treatment Satisfaction
Measure.
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show that the MTSM is able to discriminate between
patients with different symptom burden and bother-
someness. It also conﬁrms the ﬁndings published
earlier from the pilot work, suggesting the measure can
perform reliably in reﬂecting treatment satisfaction for
changes in migraine treatment.
Single-item satisfaction ratings are generally posi-
tively skewed, and can therefore be limited in the use-
fulness of their interpretation for clinical trial data
(refer to Fig. 1). The incorporation of patient-based
expectations into the equation provides a wider distri-
bution of results and an increase in the sensitivity of
satisfaction scores, which improves the distribution
(refer to Figs. 1 and 2). Data from this study show that
using the four-part individualized measure and scoring
algorithm results in an augmenting of the raw satisfac-
tion with expectations, importance, and outcomes and
minimizes the amount of positive skew of the raw
satisfaction ratings and maximizes the sensitivity of the
scores (refer to Fig. 2 and Table 5).
Although both global satisfaction and raw satisfac-
tion scores are highly correlated with the derived sat-
isfaction score (MTSM), the scoring algorithms and
weights introduce a different treatment-relevant con-
struct into the MTSM score. Therefore, the pattern
suggested is that the movement toward the more dif-
ferentiated scores is measuring something different
than addressed by the global and raw scores alone.
This is a positive ﬁnding in support of the conceptual
model and earlier ﬁndings [17], indicating the value of
measuring treatment satisfaction as affected by indi-
vidual expectations and importance.
An additional beneﬁt of the structure of the MTSM
is the ability to look at individual attributes of interest.
Because the attributes are designed to be used as indi-
vidual items, and are scored separately, one could, for
example, examine the characteristics of Item 9 on its
own to assess whether or not a given treatment was
easy to use. If this was an attribute that a company
expected greater patient preference for, it could be
selected as an individual end point and stand on its
own rather than having its effects masked as part of a
larger scale with an aggregated score. Although this
could present an advantage in measurement strategy,
the application of the individual items in this manner
would require further validation.
The design of the Duke Study excluded patients
who were not currently receiving treatment from a
neurologist, and those not currently receiving treat-
ment from a headache clinic. This effectively focused
the data set on a more severe headache population,
which limits the generalizability of the validation
results presented.
The study population was sufﬁciently large to test
the validity and sensitivity of the measure to changes in
treatment; the treatment itself (being a community-
based HMP). Some characteristics of the study popu-
lation provided a large amount of variability, such as
the inclusion of patients having a variety of prescribed
medications. We believe this may have diluted the sta-
tistical performance results. Therefore, this measure-
ment design still needs to be tested inside a randomized
controlled trial where a greater homogeneity and
control of both patients and treatment can provide a
less diffuse test of the responsiveness of the measure to
changes in medication.
To conclude, the MTSM model appears to be a
good solution to the problem we tasked ourselves with
in developing a scoring system to reﬂect the premise
Table 5 Summary of global satisfaction and derived MTSM
Global satisfaction item Derived MTSM score range
0 “The most dissatisﬁed I could be.” 2.30–10.87
1 8.08–19.46
2 7.04–17.40
3 8.77–26.09
4 7.00–29.90
5 16.38–33.84
6 17.25–35.33
7 24.57–44.39
8 26.29–56.69
9 36.49–58.34
10 “The most satisﬁed I could be.” 37.75–75.11
MTSM, Migraine Treatment Satisfaction Measure.
Table 6 Sensitivity of the MTSM
MTSM items
Mean raw sat (SD) Mean MTSM (SD)
HMP No HMP P HMP No HMP P
Attribute score: total relief 7.8 (1.9) 6.5 (2.4) 0.001 39.3 (17.7) 31.0 (16.2) 0.007
Attribute score: quick relief 7.1 (2.6) 5.6 (2.2) 0.001 34.1 (17.1) 27.1 (17.9) 0.027
Attribute score: pain free for long time 7.4 (2.4) 5.8 (2.8) 0.001 32.0 (16.9) 20.7 (16.2) 0.000
Attribute score: additional symptoms relief 7.3 (2.4) 5.8 (2.6) 0.003 29.7 (16.0) 21.3 (18.3) 0.008
Attribute score: conﬁdence in TX 7.1 (2.5) 5.5 (2.9) 0.002 32.1 (16.9) 22.9 (16.7) 0.003
Attribute score: less disruption 7.5 (2.4) 5.8 (2.4) 0.000 33.0 (16.4) 22.9 (15.2) 0.001
Attribute score: relief with one dose 6.6 (2.8) 4.8 (2.8) 0.001 26.3 (17.8) 17.1 (15.0) 0.002
Attribute score: freedom from pain return 6.9 (2.5) 5.1 (2.7) 0.000 28.2 (16.7) 19.4 (14.7) 0.002
Attribute score: easy to use 8.6 (1.8) 8.3 (2.0) 0.439 34.3 (17.1) 26.2 (14.1) 0.005
Migraine Treatment Satisfaction Score 7.9 (2.3) 6.1 (2.8) 0.000 43.2 (14.4) 31.4 (14.9) 0.000
HMP, Headache Management Program; MTSM, Migraine Treatment Satisfaction Measure;TX, treatment.
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of the conceptual model to generate a more sensitive
and meaningful indicator of patient satisfaction with
migraine treatment. This new application provides for
the inclusion of both expectations and importance in
the assessment of satisfaction with treatment. Figuring
these two traits into the satisfaction scores provides
for a truer picture of the patient’s overall treatment
experience.
The Duke Center for Clinical Health Policy Research received
limited funding from the U.S. Agency for HealthCare
Research and Policy to conduct a randomized controlled trial
of HMP at three clinical sites. The trials were aimed at
reducing headache-related disability, improving process of
care, and reducingmanagement costs for patientswith chronic
headache. Additional funds were provided to the Duke Center
by AstraZeneca to support the inclusion of the MTSM in this
community headache management intervention and support
the data collection and analytic activities required to evaluate
and validate the performance of theMTSM. AstraZeneca also
provided funds to HRA to support the analysis of the valida-
tion data collected. For further information about theMTSM,
contact: Kim Gilchrist, AstraZeneca.
Source of ﬁnancial support: The study was funded by a grant
from AstraZeneca.
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